JP2012523418A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523418A5
JP2012523418A5 JP2012504788A JP2012504788A JP2012523418A5 JP 2012523418 A5 JP2012523418 A5 JP 2012523418A5 JP 2012504788 A JP2012504788 A JP 2012504788A JP 2012504788 A JP2012504788 A JP 2012504788A JP 2012523418 A5 JP2012523418 A5 JP 2012523418A5
Authority
JP
Japan
Prior art keywords
alkyl
arylalkyl
cycloalkyl
heteroarylalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030130 external-priority patent/WO2010118055A1/en
Publication of JP2012523418A publication Critical patent/JP2012523418A/ja
Publication of JP2012523418A5 publication Critical patent/JP2012523418A5/ja
Pending legal-status Critical Current

Links

JP2012504788A 2009-04-09 2010-04-06 認知機能低下の阻害剤 Pending JP2012523418A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16798409P 2009-04-09 2009-04-09
US61/167,984 2009-04-09
US30866710P 2010-02-26 2010-02-26
US61/308,667 2010-02-26
US30909110P 2010-03-01 2010-03-01
US61/309,091 2010-03-01
PCT/US2010/030130 WO2010118055A1 (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline

Publications (2)

Publication Number Publication Date
JP2012523418A JP2012523418A (ja) 2012-10-04
JP2012523418A5 true JP2012523418A5 (enExample) 2013-05-23

Family

ID=42936539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504788A Pending JP2012523418A (ja) 2009-04-09 2010-04-06 認知機能低下の阻害剤

Country Status (12)

Country Link
US (3) US8765816B2 (enExample)
EP (1) EP2416795B1 (enExample)
JP (1) JP2012523418A (enExample)
CN (2) CN102458435A (enExample)
AU (2) AU2010234518A1 (enExample)
BR (1) BRPI1007624A2 (enExample)
DK (1) DK2416795T3 (enExample)
ES (1) ES2545795T3 (enExample)
IL (1) IL215645A0 (enExample)
RU (1) RU2595720C2 (enExample)
SG (2) SG10201404913QA (enExample)
WO (1) WO2010118055A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
BR112012002246A2 (pt) 2009-07-31 2019-09-24 Cognition Therapeutics Inc composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
HK1202248A1 (en) * 2011-08-25 2015-09-25 考格尼申治疗股份有限公司 Compositions and methods for treating neurodegenerative disease
EP2747768A4 (en) * 2011-08-25 2015-10-21 Cognition Therapeutics Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EA024767B1 (ru) 2012-03-20 2016-10-31 Адамед Сп. З О.О. Сульфонамидные производные бензиламина для лечения заболеваний цнс
AU2014342520B2 (en) * 2013-10-28 2019-08-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
EP4153209A1 (en) 2020-05-20 2023-03-29 The Board of Trustees of the University of Illinois Method for treating lysosomal storage diseases with histatin peptides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321386A (en) * 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
JPS62283922A (ja) * 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
JPH01180822A (ja) * 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995011221A1 (en) * 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CN1093079A (zh) * 1993-03-30 1994-10-05 陈英俊 由具有愈创木酚结构之香辛类化合物及其去氢化合物衍生之肾上腺素激性乙型阻断剂
DE69535461T2 (de) * 1994-10-21 2008-09-25 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-rezeptor aktive verbindungen
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
AU2002332659A1 (en) * 2001-08-21 2003-03-03 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
JP2004002517A (ja) * 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
EP1644026A4 (en) 2003-06-12 2007-10-24 Ms Science Corp SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
EP2204381A1 (en) 2005-03-05 2010-07-07 Abbott GmbH & Co. KG Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
CA2611489A1 (en) 2005-06-15 2006-12-28 Darrick S.H.L. Kim Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
US20080193573A1 (en) 2006-03-17 2008-08-14 Gow Robert T Extracts and methods comprising curcuma species
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
US7723377B2 (en) 2006-09-29 2010-05-25 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
AU2008254905A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of treating cognitive disorders by inhibition of Gpr12
EP2206707B1 (en) * 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
BR112012002246A2 (pt) 2009-07-31 2019-09-24 Cognition Therapeutics Inc composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
WO2011106785A2 (en) 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
HK1202248A1 (en) 2011-08-25 2015-09-25 考格尼申治疗股份有限公司 Compositions and methods for treating neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2012523418A5 (enExample)
RU2011145321A (ru) Ингибиторы снижения когнитивных способностей
JPWO2022138987A5 (enExample)
AU2010297557C1 (en) Lysine specific demethylase-1 inhibitors and their use
JP2013501006A5 (enExample)
CA2457444A1 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
JP2021105002A5 (enExample)
JP2013056919A5 (enExample)
CA2456606A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
RU2005103244A (ru) Производные 1h-1,2,4-триазол-3-карбоксамида в качестве лигандов рецептора каннабиноидов (cb1)
CA2462692A1 (en) Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
JP2013522325A5 (enExample)
US9682950B2 (en) Thiophene-2-carboximidamide based selective neuronal nitric oxide synthase inhibitors
WO1996018608A1 (en) Aniline derivatives having nitrogen monoxide synthase inhibitory activity
KR20200038473A (ko) 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체
JP2023518776A (ja) シクロスポリン誘導体の調製
JP2015516968A5 (enExample)
JP2017519796A5 (enExample)
AU2017202849B2 (en) Potent and Selective Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof
RU2012107457A (ru) Ингибиторы ухудшения когнитивных способностей
CA2939835A1 (en) Aminocarbonylcarbamate compounds
JP2018507230A5 (enExample)
CA2561733A1 (en) Pegylated ion channel modulating compounds
CA2671482A1 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives